Early detection of lung cancer using DNA promoter hypermethylation in plasma and sputum

Clinical Cancer Research

Volumn 23, Issue 8, 2017, Pages 1998-2005

  Hulbert, Alicia ^a,b   Jusue Torres, Ignacio ^b   Stark, Alejandro ^c   Chen, Chen ^a,d   Rodgers, Kristen ^b   Lee, Beverly ^b   Griffin, Candace ^b   Yang, Andrew ^b   Huang, Peng ^a,e   Wrangle, John ^f   Belinsky, Steven A ^g   Wang, Tza Huei ^a,b,c   Yang, Stephen C ^b   Baylin, Stephen B ^a   Brock, Malcolm V ^a,b   Herman, James G ^a,h  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Johns Hopkins University   (United States)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER STAGING; CASE CONTROL STUDY; CDO1 GENE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; HOXA7 GENE; HOXA9 GENE; HUMAN; HUMAN TISSUE; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PREDICTION; PREOPERATIVE EVALUATION; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SOX17 GENE; SPUTUM CYTODIAGNOSIS; TAC1 GENE; TUMOR GENE; ZFP42 GENE; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; EARLY CANCER DIAGNOSIS; GENE EXPRESSION PROFILING; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; SPUTUM;

AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DNA; DNA METHYLATION; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; SPUTUM; TRANSCRIPTOME;

EID: 85018821461     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1371     Document Type: Conference Paper

References (38)

1. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, BlackWC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365: 395-409.
2. Tammemagi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection criteria for lung-cancer screening. N Engl J Med 2013;368:728-36.
3. Gierada DS, Pinsky P, Nath H, Chiles C, Duan F, Aberle DR. Projected outcomes using different nodule sizes to define a positive CT lung cancer screening examination. J Natl Cancer Inst 2014;106. pii: dju284.
4. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012;307:2418-29.
5. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG.Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
6. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999;59:71-3.
7. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
8. Belinsky SA, Liechty KC, Gentry FD, WolfHJ, Rogers J, Vu K, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338-44.
9. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-28.
10. Ostrow KL, Hoque MO, Loyo M, Brait M, Greenberg A, Siegfried JM, et al. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res 2010;16:3463-72.
11. Leng S, Do K, Yingling CM, Picchi MA, Wolf HJ, Kennedy TC, et al. Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin Cancer Res 2012;18:3387-95.
12. Li L, Shen Y, Wang M, Tang D, Luo Y, Jiao W, et al. Identification of the methylation of p14ARF promoter as a novel non-invasive biomarker for early detection of lung cancer. Clin Transl Oncol 2013;16:581-9.
13. Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol 2013;31:4140-7.
14. Kim Y, Kim D-H. CpG island hypermethylation as a biomarker for the early detection of lung cancer. New York, NY: Springer New York; 2014. p.141-71.
15. Nawaz I, Qiu X,WuH, Li Y, Fan Y,HuL-F, et al. Development of a multiplex methylation specific PCR suitable for (early) detection of non-small cell lung cancer. Epigenetics 2014;9:1138-48.
16. Yang X, Dai W, Kwong DL-w, Szeto CYY, Wong EH-w, Ng WT, et al. Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. Int J Cancer 2014;136:E127-35.
17. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylationspecific PCR: a novel PCR assay formethylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
18. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
19. Bailey VJ, Keeley BP, Razavi CR, Griffiths E, Carraway HE, Wang TH. DNA methylation detection using MS-qFRET, a quantum dot-based nanoassay. Methods 2010;52:237-41.
20. Bailey VJ, Zhang Y, Keeley BP, Yin C, Pelosky KL, Brock M, et al. Single-tube analysis of DNA methylation with silica superparamagnetic beads. Clin Chem 2010;56:1022-5.
21. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
22. Wrangle J, Machida EO, Danilova L, Hulbert A, Franco N, Zhang W, et al. Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer. Clin Cancer Res 2014;20:1856-64.
23. Diaz-Lagares A, Mendez-Gonzalez J, Hervas D, Saigi M, Pajares MJ, Garcia D, et al. A novel epigenetic signature for early diagnosis in lung cancer. Clin Cancer Res 2016;22:3361-71.
24. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw 2014;12:1738-61.
25. Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 2005;11:6505-11.
26. Prindiville SA, Byers T, Hirsch FR, Franklin WA, Miller YE, Vu KO, et al. Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol Biomarkers Prev 2003;12:987-93.
27. Keeley B, Stark A, Pisanic TR2nd, Kwak R, Zhang Y, Wrangle J, et al. Extraction and processing of circulating DNA from large sample volumes usingmethylation on beads for the detection of rare epigenetic events. Clin Chim Acta 2013;425:169-75.
28. Genome Bioinformatics Group of UC Santa Cruz. UCSC genome bioinformatics. 2015. [cited 2015 Jun 30]. Available from: http://genome.ucsc.edu/.
29. Brandes JC, Carraway H, Herman JG. Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter. Oncogene 2007;26:6229-37.
30. Untergrasser A CI, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG. Primer3web. 2012. [cited 2015 Jun 30]. Available from: http://primer3.ut.ee/.
31. Team RC. R: A language and environment for statistical computing. In: R-Project Org, Version 3.0.2 ed. Vienna, Austria: R Foundation for Statistical Computing; 2013.
32. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, et al. The case for early detection. Nat Rev Cancer 2003;3:243-52.
33. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004;4:707-17.
34. Kennedy TC, Proudfoot SP, Franklin WA, Merrick TA, Saccomanno G, Corkill ME, et al. Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories. Cancer Res 1996;56:4673-8.
35. Kennedy TC, Proudfoot SP, Piantadosi S, Wu L, Saccomanno G, Petty TL, et al. Efficacy of two sputum collection techniques in patients with air flow obstruction. Acta Cytol 1999;43:630-6.
36. Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999;91:332-9.
37. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000;60:892-5.
38. Silvestri GA, Vachani A, Whitney D, ElashoffM, Porta Smith K, Ferguson JS, et al. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med 2015;373:243-51.